|
|
Speakers 
 Dr. Alahari Arunakumari,
Director, Process Development Division,
Medarex, USA
Dr. Alahari Arunakumari is currently working at Medarex, NJ as Senior Director of Process Development Department, focusing on the development and transfer of cell culture and purification processes to internal manufacturing as well as outside CMOs. She has held different corporate positions in Biotech and Pharmaceutical companies in US for the past 16 years. She has extensive and collective experience in microbial fermentation, mammalian cell culture and purification of biologics at Enzon Inc., BMS and Medarex. At Medarex she has been conducting process research and optimization for Humab integrated process designs with CHO cell culture processes in combination with non-ProteinA platform technologies to reduce manufacturing timelines and improve the production economics.
|
 Mr KV Balasubramaniam,
Managing Director,
Indian immunologicals Ltd., India
Mr K V Balasubramaniam, Managing Director, Indian Immunologicals Ltd holds a graduate degree in Mechanical Engineering from the Madras University (1979) and a masters degree in management from the Indian Institute of Management, Ahmedabad ( 1981).
He has over 25 years experience in managing industrial enterprises, with nearly 20 years in the pharmaceutical industry. He joined Indian Immunologicals in 1996 as Chief Executive and has been instrumental in reviving the fledgling unit of the National Dairy Development Board and making it a professionally managed, performance driven and result oriented vaccine player. He was inducted into the Board as Managing Director in 1999.
Indian Immunologicals is today the No 1 animal vaccine player , the 3rd largest animal health company and the 8th largest biotech company in India.
Mr Balasubramaniam’s key area of expertise has been in general management, starting new businesses, turn around management and project management.
Mr Balasubramaniam has been a speaker on both the subject of management and on bio-technology in various national and international forums.
|
 Dr. Subir Basak,
General Manager,
Biocon, India
Dr. Subir Basak is the General Manager – Business Development at Biocon. He joined Biocon in 2005 and is responsible for Global business development and the Oncotherapeutics and Inflammation Business Units. As part of his responsibility he manages in-licensing, outlicensing, and strategic alliances and was instrumental in driving the alliance between Biocon and Abraxis Biosciences. The Business Units are dedicated to the successful development, manufacturing and commercialization of biopharmaceutical products such as monoclonal antibodies and novel NDDS therapies to cater to the unmet needs of cancer and inflammation patients worldwide. Biocon has an impressive portfolio of novel candidates at exciting stages in the pipeline for cancer and other auto-immune diseases. BIOMAb EGFRTM, India’s first monoclonal antibody cancer drug for Head and Neck Cancer was launched under the able leadership of Dr. Basak and his sales and marketing team.
Prior to joining Biocon, Dr. Basak was with Amgen, the world's largest Biotech company as Global Operations Leader. At Amgen he managed the Global Operations of 5 proprietary products, in mainly North America, Europe, and Japan. He was also the Marketing Manager for the GCSF franchise (Neupogen and Neulasta) and launched Neulasta as part of the global team. Prior to Amgen, Dr. Basak held senior management roles at Bayer in the Biologics and Biopharmaceuticals business. He began his career at Merck Research Labs in 1992.
Dr. Basak completed his MBA from the Kellogg School of Management in 2002 and his MS and PhD at Purdue University in 1995. In 1987, he finished his BE in Chemical Engineering at IIT Roorkee with 1st Class Honors.
He is the recipient of several awards including the Bayer Innovation Award from Bayer Corporation, the Merck Fellowship from Merck & Company, the Andrews Board Fellowship from Purdue University and the Sir. P C Ray Award from the Indian Chemical Engineering Congress. He has authored 5 peer reviewed Journal articles and has been an invited speaker at over 20 global conferences.
In his spare time, Dr. Basak enjoys reading, playing tennis, and spending time with his children.
|
 Mr. S G Belapure,
President and Head of Manufacturing,
Zydus Cadila, India
His current position is President – Manufacturing (Formulations) in the Organization and Looking after the entire Formulation Manufacturing facilities of Zydus Group Companies.
He is instrumental in bringing USFDA, MCA, ANVISA Brazil, MOH Tanzania MOH Oman, MCC South Africa and PIC Romania to the company.
He was earlier the Director Operations at MJ Pharma Ltd. US FDA approved facility.
His total experience is of 29 years in various pharmaceutical companies,like Lederle, Sun Pharma & Cipla.He has vast experience in the related fields of manufacturing ,Bulk drugs(API),QA and administration.
He has been instrumental in getting USFDA,TGA Australia, MCA – UK and MCC South Africa approvals during his tenure in the companies like Cipla,MJ pharma & Sun Pharma.
|
 Dr. Anil Chawla,
Vice President & Head of Vaccine R&D,
Panacea Biotec, India
|
 Dr. Louis-Christian Claus,
Director of Biologic Project Development,
BioScience, Baxter, France
|
 Dr John Curling,
President,
John Curling Consulting, Sweden
John Curling works as an independent consultant and is currently Senior Scientist and Consultant with ProMetic BioSciences Ltd. He is also a member of the Scientific Advisory Committee of the company and is a consultant to the Core Management Team of the ProMetic – American Red Cross joint Plasma Protein Purification Project.
After graduating in chemistry from the University of Sussex, UK, John Curling entered the laboratory and industrial purification arena in 1967 and started to build a process chromatography business at Pharmacia in 1972. Research on blood plasma proteins was carried out primarily during the period 1972-1982. He held various management positions and was President of Pharmacia’s Process Separation Division from 1984 until 1990. In the early 1980’s John Curling was also Marketing Director in a Joint Venture partnership with the engineering and fermentation company Alpha Laval AB/Chemap AG. In 1986 he was involved in a major acquisition (LKB Produkter) and the subsequent integration and rationalisation of the merged companies.
He is the author of numerous publications and was a contributor and editor of “Methods of Plasma Protein Fractionation”. He is on the Editorial Advisory Board of “BioPharm International”.
John Curling was Chairman of the Board of the ‘‘Recovery Conference Series’’ from 2001 to 2003, and was a Co-chair of the “Recovery of Biological Products 10” Conference held in Mexico in 2001. He has also worked as a Temporary Advisor and Consultant to the World Health Organisation South East Asia Region on technologies for blood plasma fractionation.
|
 Mr Patrick Deruytter,
Operations Director for Asia Pacific,
Emerson Process Management, Singapore
Mr Deruytter is Director of Emerson’s Engineering & Services in Singapore where he has overall responsibility for all operations, project executions and services for the Systems and Solutions division in Asia Pacific. His expertise includes the management of large project portfolio in the oil and gas, petro-chemical, chemical, mining and pharmaceutical industries. He has also developed and introduced new services such as SIS (safety instrumented services), APC (advanced process control), PIMS and MES in the AP region.
Mr Deruytter has a Master of Process Automation as well as a Bachelor of Industrial Engineer Electronics from the Industriele Hogeschool v/h Rijk Gent (Belgium). He then completed his management program at the Minnesota Management Institute, University of Minnesota. He began his career as an Instrumentation Engineer for ABAY, then progressed to Systems Engineer for Fisher Controls in Belgium. He was then Project Engineer for Fisher-Rosemount Belgium in 1993, during which, he advanced from Technical Service Manager to Service Manager. From 1997 onwards, he was relocated as Marketing Director for RS3 in Fisher-Rosemount in USA where he assumed full responsibility for the worldwide marketing & North America sales for RS3. After year 2000, he went on as Marketing Director Systems for Emerson Process Management EMA (previously Fisher-Rosemount); advanced to Project Director for Emerson Process Management and in 2003 came to where he is now, Director of Engineering & Services Asia Pacific. During the period of his studies and career, he has also accomplished numerous scholarship programs.
Mr Deruytter can converse up to 4 languages and has more than 20 years of industry experience behind him.
|
 Dr. William Downey,
President,
High Tech Business Decisions, USA
Mr. Downey is president and managing director of HighTech Business Decisions, a consulting company that specializes in market research for business-to-business biotechnology, pharmaceutical manufacturing, medical and electronic products. HighTech Business Decisions has been serving the biopharmaceutical contract manufacturing industry for over ten years. Mr. Downey has over 25 years of industry experience, and he has held various positions in marketing, sales, strategy and finance for both private and public companies. Mr. Downey holds a Masters in Business Administration from Washington University in St. Louis and Bachelors from the University of Michigan in Ann Arbor
|
 Dr Hartmut Ehrlich,
Vice President for Global Clinical Research and Development,
Baxter AG, Austria
Dr. Hartmut Ehrlich is a physician with over 20 years experience in biopharmaceutical research and product development. He graduated from Medical School at the University of Giessen, Germany in 1985 and completed his Doctorate at the Clinical Research Unit for Blood Coagulation and Thrombosis of the Max-Planck-Foundation. Subsequently, he spent over 6 years in basic research and patient care at the Department of Medicine, Hematology-Oncology of Indiana University and the Lilly Laboratories for Clinical Research in Indianapolis, Indiana, the Department of Molecular Biology at the Central Laboratory of the Dutch Red Cross in Amsterdam, The Netherlands, and the Kerckhoff-Clinic of the Max-Planck-Foundation in Bad Nauheim, Germany.
In 1991, Dr. Ehrlich joined industry and spent almost 4 years in clinical development as well as corporate project management in immunology-oncology at Sandoz, now Novartis, in Nuremberg, Germany and Basel, Switzerland.
Dr. Ehrlich joined Baxter in 1995 as Medical Director for its former Biotech business, and held several positions of increasing responsibility until September 2003 when he was named Vice President, Global Clinical R&D for the BioScience Division. In September of 2006, he was promoted to his current position, leading all R&D efforts for BioScience.
During his career, Dr. Ehrlich has authored and co-authored well over 100 scientific publications and book chapters. Most importantly, he was associated with the successful development and licensure of numerous biotechnological products in the areas of hematology – oncology, immunology, critical care, hemophilia, vaccines and biosurgery.
|
 Mr. P.A. Francis,
CEO,
Saffron Media, India
Mr.P.A.Francis is the CEO of Saffron Media Pvt Ltd Mumbai and Editor of two of its well known media products, Pharmabiz.com and Chronicle Pharmabiz. Prior to this assignment, he was the Editor of Business Publication Division of Indian Express Group where he launched Express Pharma Pulse, the first weekly newspaper for Indian pharmaceutical industry, and six other industry specific news publications.
Mr.Francis is a financial journalist of more than 30 years of standing with work experience in The Times of India, The Economic Times, Observer of Business & Politics and Indian Express. He is a reputed pharmaceutical expert with in depth knowledge of Indian pharmaceutical industry and its diverse regulatory affairs. His powerful editorial comments in Pharmabiz every week on various issues in the pharmaceutical industry is widely read by top pharma executives and taken note by the Indian government.
Mr.Francis had widely travelled to participate and speak at various international and national pharmaceutical conferences. He was invited by Indian Business Alliance, Moscow in June,2004 and Marketing Association of Pakistan in October ,2004, to speak on Indian pharmaceutical industry. He was also invited to moderate a session on South Asian pharmaceutical industry at INTERPHEX, New York in April,2007.
|
 Dr B M Gandhi,
Former Advisor for International Cooperation, Medical Biotechnology & Infrastructure,
Ministry of Science and Technology, India
|
 Dr N.K Ganguly,
Director General,
Indian Institute of Medical Research, India
|
 Dr Lallan Giri,
Vice President, Science and Business Relations,
Emergent Biosolutions Inc, USA
Currently Vice President of Scientific Affairs. Manages scientific and technology aspects in the commercial development of vaccines, evaluation and in-licensing of technology, and identifies potential candidates for collaborations, partnership, and merger and acquisition.
Formerly he was responsible for Research and Development, Regulatory Affairs, and Quality Operations at BioPort Corporation, Lansing, Michigan site. He led a team at the Bioport Coporation, Lansing, Michigan to the successful approval of the Anthrax vaccine manufacturing facility and BLA. Before joining BioPort Corporation in 2000 he held the position of Executive Director of Quality Operations and Regulatory Affairs (1993 -1999) at the Glaxo Wellcome Biopharmaceutical Inc (GWBI) and was responsible for getting the GWBI approved by FDA for the manufacture and distribution of a – interferon (Wellferon™) for Hepatitis C indication. He also held the position of Director of Analytical Development and Quality Control at the Aventis Pasteur
( formerly Pasteur Merieux Connaught ), in the US (1989-1993). While in this position played a key role in the development and licensing of five vaccines for adult and pediatric indications.
Earned a Ph. Degree in Biological Sciences from the University of Montana (1974), U.S.A. and Post-Doctoral training in protein chemistry from the Max Planck Institute of Molecular Genetics, Germany (1975-1978). Held academic appointment at the University of Massachusetts in Biochemistry (1979-1983) where he taught Biochemistry and conducted research RNA – Protein interaction and structure and function of Ribosomes. He then took his first Industrial position as Manager of R&D in Pharmacia, USA where he led a team in peptide and DNA synthesis and purification research (1983-1989). In total, Dr. Giri has 23 years of Biopharmaceutical industry plus 8 years of academic (research and teaching) experience.
|
 Dr Uwe Gottschalk,
Group Vice President - Purification Technologies,
Sartorius Stedim Biotech, Germany
Dr. Gottschalk is Group Vice President, Purification Technologies, with a global responsibility for bioseparation products at Sartorius Stedim Biotech. He worked in different capacities for Bayer Health Care from 1991-2004 and became head of the GMP protein purification facility in Wuppertal (Germany). He was responsible for the production of monoclonal antibodies and other recombinant proteins using various expression systems.
Dr. Gottschalk holds a Ph.D. in Chemistry from the University of Münster. He is member of BioPharm International’s editorial advisory board and has written one book, five book chapters and many other publications in the areas of biotechnology and somatic gene therapy. In academia Dr. Gottschalk is Head Lecturer at the University of Duisburg–Essen (Germany) and also lectures at the Ecole Polytechnique Fédérale de Lausanne EPFL (Lausanne, Switzerland).
Dr. Gottschalk is board member of the VBU Association of German Biotech Companies.
|
 Dr Eric Grund,
Director, Fast Trak Biopharma Services,
GE Healthcare, Sweden
Eric Grund has worked in the field of biomolecule purification for about 30 years. He presently heads a group in GE focussed on supporting bioprocess applications world-wide and is based in Bangalore, India. He has authored a number of chromatography technique handbooks, as well as monographs on monoclonal antibody purification and protein purification. Over his career, he has been involved in the development of well-known products for affinity chromatography, gel filtration, ion exchange chromatography and hydrophobic interaction chromatography, as well as equipment for chromatography. Over the last ten years his focus has been on large-scale industrial purification of biomolecules.
|
 Dr S.K. Gupta,
Director General & Dean,
Institute of Clinical Research India, India
Professor Suresh K. Gupta is currently Dean of Institute of Clinical Research (India) the Pioneering Institute of the country. He served as Professor and Head, Department of Pharmacology at the All Indian Institute of Medical Science (AIIMS), the Premier Institution of India. Following postgraduate and post doctoral education and research in Pharmacology at AIIMS for four decades. Dr. Gupta received training in UK as a Commonwealth Fellow in at the University of Strathdyde Glasgow Scotland. Prof. Gupta is responsible for establishing the National Pharmacovigilance Centre at AIIMS, recognized by the WHO Uppsala Monitoring Centre, Sweden and Drugs Controller General India.
Professor Gupta has received Research Grants from WHO, CSIR, DBT, ICMR, DST, Min. of Family & Welfare, Govt. of India to work on Drug Development in different disease area’s of National Importance. Professor Gupta has been the Organizing Secretary of the several International Conferences.
Professor Gupta has been the recipient of many Academic Distinctions and Awards, which includes Fellow of the Indian Pharmacological Society, Fellow International Academy of Cardiovascular Sciences (Canada), Fellow ISER (USA), Founder President of IOPS and President Indian Pharmacological Society, Hamdard National Foundation, Award. Dr. Gupta was conferred Distinguished Services Award in Medicine & Surgery by International Academy of Cardiovascular Sciences. He is also Emeritus Professor of the Indian Council of Medical Research. Published 350 research papers in prestigious journal and edited & books.
|
 Mr. Maik Jornitz,
Group Vice President for Marketing and Product Development,
Sartorius Stedim Biotech, USA
MAIK W. JORNITZ is Group Vice President Product Management Filtration | Fermentation Technologies at the Sartorius Stedim Biotech Headquarters North America, Edgewood, USA. With over 20 years of experience, Mr. Jornitz supports the biopharmaceutical industry on a world-wide basis, in particular in validation, integrity testing, membrane filtration of air and liquids. An executive board member of PDA, and member of ISPE, ASTM and DIA, he is the author and co-author of over 70 professional papers. Additionally he is author and co-author of 8 books and 6 book chapters on membrane filtration, integrity testing, and validation studies. He holds several patents related to integrity testing and filter housing designs and is the founder of Bioprocess Resources LLC. Mr. Jornitz received his Diploma in Bioengineering at the College for Advanced Technology in Hamburg, Germany and accomplished his PED at the IMD Business School, Lausanne, Switzerland.
|
 Dr. Avinoam Kadouri,
CEO,
Rainbow Biotechnologies (Sarl), Switzerland
Dr Kadouri is one of the leading scientists in Industrial biotechnology with worldwide reputation. He has 15 years of experience as R&D Director and worldwide Process development Director in Serono International. Until 2007 Dr. Kadouri was the Chairman of ACTIP (Animal Cell Technology Industrial Platform), an important European Organization of the major Biotech Companies in Europe. He is a member of several Scientific Advisory Boards of a leading biotech companies in US, Europe and Israel.
Prior to working in the industry Dr. Kadouri spent many years in a leading research Institutes, Universities and as an Associate Professor. He has published a large number of papers in life science and biotechnology and holds several applied patents. Dr. Kadouri is a key guest speaker in many major international conferences in biotechnology at the US and Europe.
|
 Dr. Daniel Karrer,
Founder,
Bioproject GmbH, Switzerland
|
 Dr. Gerhard Klement,
CEO & President, Biopharmaceuticals,
Reliance Life Sciences, India
Gerhard F. Klement currently serves as CEO & President for Reliance Biopharmaceuticals. Reliance Biopharmaceuticals is part of Reliance Industries, the largest company in India. He is with Reliance since July 2006. The main goal of Reliance is to establish a global Biotechnology company. Within his role he is responsible for the production of recombinant Proteins and MAB, Blood Plasma Products, Vaccines and API’S.
Prior to joining Reliance he served as VP Manufacturing & Technical Operations for ALTUS Pharmaceuticals. Within this role he was leading the manufacturing, process development, formulation and analytical operations for ALTUS.
Mr. Klement served as Chief Technology Officer for the worldwide Biologics and Chemicals Group at Lonza, where he was responsible for new technologies and business development. From 2003 to 2005 Mr. Klement was the Head of Operations, USA and Chief Operating Officer Biopharmaceuticals, Worldwide at Lonza Biologics.
Previously, Mr. Klement held various positions in manufacturing and engineering at Serono and Centocor. Mr. Klement also serves on the Scientific Advisory Board of the New Hampshire Chamber of Commerce and the Scientific Advisory Board of Laureate Pharmaceuticals. He served as well on the board of directors for the New Hampshire. Mr. Klement holds a B.SC. from the University of Agriculture in Vienna, Austria. He received executive training in general management and leadership from IMD and Babson College.
|
 Dr. Shankar Musunuri,
Senior Director & Strategic Product Leader,
Wyeth Biotech, USA
Shankar Musunuri is Senior Director and Strategic Product Leader at Wyeth Biotech in Collegeville, Pennsylvania. He provides manufacturing operations and product supply leadership for some key biotechnology products. He leads cross-functional/multisite product councils (global teams) that are responsible for meeting product objectives and business plan milestones while achieving supply chain excellence throughout the life-cycle of the products. He has been at Wyeth for over 11 years in various roles of increased responsibilities in the areas of R&D, strategy, alliance management, manufacturing and supply chain operations. Prior to joining Wyeth, Dr. Musunuri worked for Amylin Pharmaceuticals, Inc., San Diego, as a Senior Staff Scientist and the Head of Pharmaceutics. Earlier in his career, Dr. Musunuri worked for McNeil Consumer Products Company in drug delivery research.
Dr. Musunuri obtained his MBA (Global Executive) from the Duke University’s Fuqua School of Business and Ph.D. in Pharmaceutics from the University of Connecticut. Dr. Musunuri has authored numerous scientific papers, abstracts, and patents. Dr. Musunuri is a member of Editorial Advisory Board of the AAPS journal. He served as the Chair (founding) of the San Diego Pharmaceutical Forum, the Chair of AAPS Biotec Section (elected position) in 1999, and Co-Chair of the AAPS National Biotechnology Conference in 2004.
|
 Dr. Gopalan Narayanan,
Head, Biologicals and Biotechnology unit, Licensing Division,
Medicines and Healthcare Products Regulatory Agency (MHRA), UK
|
 Mr. Vikram Paradkar,
Vice President, Process Development,
Reliance Life Sciences, India
Dr. Vikram Paradkar is the Vice President of Process Development in Reliance Biopharmaceuticals in Navi Mumbai, India. He is responsible for providing guidance and oversight to process development, technology transfer and technical support for all aspects of therapeutic protein manufacturing. The portfolio of products under development include proteins derived from microbial fermentation, mammalian cell culture and plasma fractionation include cytokines, receptor proteins, monoclonal antibodies, enzymes and plasma proteins. Current technology transfer projects underway at Reliance Biopharmaceuticals involve manufacturing facilities spanning a range of capacities, equipment set-ups and overall production requirement. His prior assignments were as the Director of Process Technical Services in Wyeth Biotech in Massachusetts, USA; the Manager of Protein Purification in Bayer Biological Products in California, USA and the Manager of Bioprocess in Monsanto Corporation in Wisconsin, USA. He received his PhD in Chemical and Biochemical Engineering from University of Iowa, USA and his Bachelors in Chemical Engineering from University Department of Chemical Technology from Mumbai, India.
|
 Mr. T S Parmar,
Vice President of Strategic Planning & Business Development,
Zydus Cadila, India
|
 Dr. Dhananjay B. Patankar,
Chief Technical Officer,
Intas Biopharmaceuticals, India
Dr. Patankar has been heading the development and manufacturing of recombinant biotechnology products at Intas Pharmaceuticals for the past 6 years. He has a total of 11 years of experience in the Indian Biotechnology industry. In his career he has been associated with th development of 7 recombinant products which are currently marketed in India.
Dr. Patankar is a chemical engineer from IIT Mumbai and did his Masters and PhD from the University of Utah in the US, followed by a postdoctoral fellowship at Rutgers University in the US.
In 2004 Dr. Patankar was an industry representative on the National Task Force headed by Dr. Mashelkar for the streamlining of the regulatory approval procedure for Biotechnology products.
|
 Dr. T S Rao,
Adviser, Department of Biotechnology,
Ministry of Science and Technology, India
Dr. T.S.Rao at present working as Adviser in the Department of Biotechnology, Ministry of Science & Technology, Govt. of India and looking after the programmes related to Medical Biotechnology, Vaccines & Diagnostics, Human Genetics & Genome Analysis including Gene Therapy, National Bioethics Committee, development of new and improved vaccines through Indo-US Vaccine Action Programme and also looking after the two human vaccine production units established under Technology Mission on Immunization, namely BIBCOL and IVCOL, in order to become self sufficient in some of the EPI vaccines specially polio, measles, BCG etc. in addition to National Brain Research Centre, an autonomous institution of Department of Biotechnology including setting up of Translational Health Science and Technology Institute and Translational Research centres.
Before joining Department of Biotechnology in 1988, Dr. Rao worked in the area of development of Malaria vaccine by using molecular biology methods and developed monoclonal antibodies for blood stages of P.falciparum and also developed in vitro culture of P.falciparum at National Institute of Communicable Diseases, Delhi.
Dr. Rao has about 18 scientific publications and popular articles to his credit in National and International Journals in the area of Vaccines, Genetics, and other areas of molecular biology and immunology. He is also one of the co-author’s of a comprehensive book entitled “An introduction to Biotechnology principals, techniques applications and industrial opportunities” published in English and Hindi by Kitab Mahal in 1992.
Dr. Rao is also the member of many National/International Committees including inter-ministerial committees to implement programmes related to medical area including human genetics & genomics, National Technical Committee of M/o Health & Family Welfare on new and improved vaccines in EPI programme, HMSC, bioethics etc.
|
 Dr. P. Bharata Ratnam,
Head, Downstream Processing,
Intas Biopharmaceuticals, India
|
 Dr. Satish Ravetkar,
Senior Director,
Serum Institute of India, India
|
 Dr. Suma Ray,
Process Development Scientist,
Sartorius Stedim Biotech
|
 Dr. Cartik Reddy,
Vice President of Biologics,
Dr Reddy's Laboratories, India
Dr. Cartikeya Reddy, Vice President, Dr. Reddy’s Laboratories Limited, heads the Biologics Division of the company which focuses on biosimilars for India as well as global markets. Dr.Reddy’s has launched two biosimilar molecules (filgrastim and rituximab) in India and a few other Countries and is working on several other products for development.
Prior to his current assignment, Cartik had worked with Genentech Inc, South San Francisco, USA, where he was a Group Leader in the Cell Culture and Fermentation R & D Department. From 1996-2001, he was with the Biotechnology Division of Bayer Corporation, Berkeley, USA, where as a Staff Scientist, he had successfully led teams in the areas of Bioprocess Development & Pilot Scale manufacturing.
Cartik holds a MS and Ph.D. in Chemical Engineering from the University of Illinois, Urbana, USA, and was a visiting scholar at the Massachusetts Institute of Technology, Cambridge, USA. He had earlier graduated with a B.Tech in Chemical Engineering from the Indian Institute of Technology, Chennai, India.
|
 Dr. Marty Siwak,
Director, Process Technology Group,
Millipore, India
|
 Dr Lee Smith,
Function Director, Process & Analytical Development,
SynVax Pte Ltd., Singapore
Lee Smith currently directs the Process and Analytical Development functions at SingVax Ltd, a Singapore based product development company founded in 2005. Lee has been working in the biopharmaceutical industry for over ten years and has experience of monoclonal antibody therapies as well as on live virus, bacterial vaccines, recombinant subunit and DNA vaccines.
He was previously Director of Development at Emergent BioSolutions, UK where he played a key role in a number of successful clinical trial submissions and out-licencing activities involving ‘Big Pharma’. Prior to that, he spent five years at GlaxoSmithKline running an R&D analytical group in London working on biotech products at all phases of development.
Lee trained as a Biochemist and holds a Ph.D. from the University of Bath (1997), U.K.
|
 Mr. Narayanan Suresh,
Chief Editor,
Biospectrum, India
Narayanan Suresh is the Group Editor of BioSpectrum and Life Sciences Group of CyberMedia. Published by CyberMedia since March 2003, from Bangalore and since March 2006 from Singapore BioSpectrum is India’s first and only Biotechnology business magazine and now Asia’s leading Life Sciences magazine He has been tracking the growth and strides made by Indian technology sector for 20 years, first for The Times of India. Suresh is also a consulting editor for CyberMedia’s flagship India and later for CyberMedia Publications IT magazine, DATAQUEST.
Suresh is sought after as an analyst of India’s technology business trends and interacts with a cross section of stakeholders in the Indian biotech sector.
Suresh started his careers as The Times of India’s first Science and Technology Correspondent in 1986 and has written extensively on major developments in nuclear, space, energy, agriculture, biotech, pharma and information technology sector. He covered various developments in the patents sector. It was his report about the patenting of turmeric by researchers in the US in the Times of India in 1995 which alerted the Indian governments which got it revoked from the US Patent Office after a two-year legal proceedings. Suresh has exposed various other major developments in the patents segment in the last decade. He has presented many papers on the issue in the United Nations, UNEP and other institutions.
Currently Suresh works from Bangalore. He is a Masters in Physics from University of Hyderabad. He has travelled extensively to attend and also make presentations on Indian technology sector in over 25 countries. He is an avid reader of technology books and literature, listens to carnatic music and speaks five langauges—English, Tamil, Malayalam, Hindi and French. He loves traveling and drives around the country regularly. He lives in Bangalore with wife Madhuri and son, Shashank, 12, and daughter, Ambika, 10.
|
 Dr. Satish Totey,
Chief Scientific Officer,
Stempeutics, India
Satish Totey is Director, Manipal Institute of Regenerative medicine and Chief Scientific Officer, Stempeutics research Pvt. Ltd. He did his DVM and MS in Veterinary Medicine and PhD from Jawaharlal Nehru University, New Delhi. He carried out postdoctoral research at University of Wisconsin, Madison and National Institute of Health, Bethesda, Maryland. He spent around 20 years at National Institute of Immunology, New Delhi and his research interest was molecular signaling during pre-implantation embryos. He is pioneered in transgenic research in India and developed more than 17 transgenic mice lines for several human diseases. He also worked on gene knockout and studied TGF beta knockout animals. He was also working on human and ovine growth hormone and expressed these proteins in E.coli and achieved highest ever yield in fed batch culture.
He was among a small number of researchers who pioneered the isolation and characterization of pluripotent stem cells from human embryo, which provided an important framework for the development of human embryonic stem cells
His derived human embryonic stem cells lines have been listed in NIH stem cell registry. He has also developed up-scaling of mesenchymal stem cells and currently conducting phase-I and II clinical trials for myocardial infarction, leg ischemia, cerebral stroke and Multiple Sclerosis.
He has 90 research papers to his credits and 12 US patents.
His research group currently focuses on the extrinsic factors involved in maintenance of the pluripotent state in human embryonic stem cells, and those factors that drive their commitment into progenitor cells representative of the three embryonic germ layers.
|
 Dr M Venkateswarulu,
Drug Controler General,
Central Drugs Control Administration, India
|
 Dr. V K Vinayak,
President, Biopharmaceutical R&D,
Panacea Biotec, India
|
 Dr Alexander Von Gabain,
Chief Scientific Officer,
Intercell, Austria
Alexander von Gabain, PhD, is CSO of Intercell AG a research-driven biotech company in Vienna and Full Prof. of Microbiology at the University of Vienna (leave of absence). In 1998, he founded Intercell and led the company as CEO from a spin-off to a publicly listed vaccine company (2005, ICLL; Vienna Stock Exchange) with today approx. 200 employees worldwide. Previously, he was Chairman of the Department of Microbiology and Genetics at the renowned research Campus of the Vienna Biocenter/IMP. Alexander von Gabain’s scientific career has taken him to institutions such as the Universities of Heidelberg and Stanford as well as to the Karolinska Institute in Stockholm, where he served as professor of medical biotechnology and is today foreign adjunct professor of vaccinology. His research interest is in the field of microbial gene expression, host-parasite interactions and immunology. The results of his research in gene expression have found their way into advanced textbooks on bacterial physiology. He is a member of several professional organizations, is in the supervisory board of biotech enterprises, co-edits scientific journals and has organized countless high impact conferences.
|
 Dr Joe Zhou,
Scientific Director, Process Development,
Amgen, USA
Dr. Joe X Zhou is a Principal Scientist at Process Development Department, Amgen Inc. Dr. Zhou’s expertise is in non-cGMP and cGMP protein/antibody therapeutics purification/production. He has experience in all aspects of process research, process optimization, viral clearance, and characterization as well as laboratory set up and project management. Dr. Zhou accomplished six patent applications and five process publications after since Amgen in 2004. Dr. Zhou has received many awards and has been invited as a speaker for many international conferences. He has over 45 full research articles and 12 abstracts published in peer- reviewed journals. Dr. Zhou is also a co-author for six registered US patents before Amgen. Dr. Joe Zhou has his Ph.D. degree in Biopharmaceutical Sciences from Queen’s University of Belfast, M.S. in Enzymology/Biochemistry and B.S. in Microbiology from Liaoning University. He has been a member of American Association of Pharmaceutical Scientists for over 10 years and currently is a member of American Chemistry Society.
|
|
|
|
